Literature DB >> 32914395

Impairments in Peripheral Blood T Effector and T Regulatory Lymphocytes in Bipolar Disorder Are Associated with Staging of Illness and Anti-cytomegalovirus IgG Levels.

Michael Maes1,2,3, Joao Victor Nani4, Cristiano Noto5, Lucas Rizzo6, Mirian A F Hayashi4,7, Elisa Brietzke8,9.   

Abstract

There is now evidence that, based on cytokine profiles, bipolar disorder (BD) is accompanied by simultaneous activation of the immune-inflammatory response system (IRS) and the compensatory immune-regulatory system (CIRS), and that both components may be associated with the staging of illness. Nevertheless, no BD studies have evaluated the IRS/CIRS ratio using CD (cluster of differentiation) molecules expressed by peripheral blood activated T effector (Teff) and T regulatory (Treg) subpopulations. This study examined Teff/Treg subsets both before and after ex vivo anti-CD3/CD28 stimulation using flow cytometric immunophenotyping in 25 symptomatic remitted BD patients and 21 healthy controls and assessed human cytomegalovirus (HCMV)-specific IgG antibodies. BD is associated with a significantly lowered frequency of unstimulated CD3 + CD8 + CD71+ and CD4 + CD25 + FOXP3 and increased CD4 + CD25 + FOXP3 + CD152+ frequencies and with lowered stimulated frequencies of CD3 + CD8 + CD71+, CD4 + CD25 + FOXP3 + CD152+, and CD4 + CD25 + FOXP3 + GARP cells and, consequently, by an increased stimulated Teff/Treg ratio. Moreover, the number of manic, but not hypomanic or depressive episodes, is significantly and negatively associated with the stimulated proportions of CD3 + CD4 + CD154+, and CD69+ and CD71+ expression on CD4+ and CD8+ cells, while duration of illness (≥ 10 years) is accompanied by a depleted frequency of stimulated CD152+ Treg, and CD154+ and CD71+ CD4+ T cells. BD and anti-human cytomegalovirus (HCMV) IgG levels significantly interact to decrease the expression of CD4 + CD25 + FOXP+GARP T phenotypes. In conclusion, in BD patients, immune injuries, staging, and HCMV seropositivity interact and cause CIRS dysfunctions and exaggerated IRS responses, which play a key role in parainflammation and neuroaffective toxicity. HCMV seropositivity contributes to an immune-risk phenotype in BD.

Entities:  

Keywords:  Bipolar depression; Cytokines; Inflammation; Neuroimmunomodulation; Psychoneuroimmunology; Staging

Mesh:

Substances:

Year:  2020        PMID: 32914395     DOI: 10.1007/s12035-020-02110-1

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  47 in total

1.  Clinical staging in psychiatry: a cross-cutting model of diagnosis with heuristic and practical value.

Authors:  Jan Scott; Marion Leboyer; Ian Hickie; Michael Berk; Flavio Kapczinski; Ellen Frank; David Kupfer; Patrick McGorry
Journal:  Br J Psychiatry       Date:  2013-04       Impact factor: 9.319

2.  Differences in the immune-inflammatory profiles of unipolar and bipolar depression.

Authors:  Andre R Brunoni; Thitiporn Supasitthumrong; Antonio Lucio Teixeira; Erica Lm Vieira; Wagner F Gattaz; Isabela M Benseñor; Paulo A Lotufo; Beny Lafer; Michael Berk; Andre F Carvalho; Michael Maes
Journal:  J Affect Disord       Date:  2019-10-30       Impact factor: 4.839

3.  Cytokine alterations in bipolar disorder: a meta-analysis of 30 studies.

Authors:  Amirhossein Modabbernia; Shervin Taslimi; Elisa Brietzke; Mandana Ashrafi
Journal:  Biol Psychiatry       Date:  2013-02-16       Impact factor: 13.382

4.  Early Life Trauma Predicts Affective Phenomenology and the Effects are Partly Mediated by Staging Coupled with Lowered Lipid-Associated Antioxidant Defences.

Authors:  Michael Maes; Ana Congio; Juliana Brum Moraes; Kamila Landucci Bonifacio; Decio Sabbatini Barbosa; Heber Odebrecht Vargas; Gerwyn Morris; Basant K Puri; Ana Paula Michelin; Sandra Odebrecht Vargas Nunes
Journal:  Biomol Concepts       Date:  2018-11-20

Review 5.  The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications.

Authors:  S Moylan; M Maes; N R Wray; M Berk
Journal:  Mol Psychiatry       Date:  2012-04-24       Impact factor: 15.992

6.  Does stage of illness impact treatment response in bipolar disorder? Empirical treatment data and their implication for the staging model and early intervention.

Authors:  Michael Berk; Alan Brnabic; Seetal Dodd; Katarina Kelin; Mauricio Tohen; Gin S Malhi; Lesley Berk; Philippe Conus; Patrick D McGorry
Journal:  Bipolar Disord       Date:  2011-02       Impact factor: 6.744

7.  Development of a Novel Staging Model for Affective Disorders Using Partial Least Squares Bootstrapping: Effects of Lipid-Associated Antioxidant Defenses and Neuro-Oxidative Stress.

Authors:  Michael Maes; Juliana Brum Moraes; Ana Congio; Kamila Landucci Bonifacio; Decio Sabbatini Barbosa; Heber Odebrecht Vargas; Ana Paula Michelin; Andre F Carvalho; Sandra Odebrecht Vargas Nunes
Journal:  Mol Neurobiol       Date:  2019-03-25       Impact factor: 5.590

Review 8.  The Compensatory Immune-Regulatory Reflex System (CIRS) in Depression and Bipolar Disorder.

Authors:  Michael Maes; Andre F Carvalho
Journal:  Mol Neurobiol       Date:  2018-04-02       Impact factor: 5.590

9.  Brain-derived neurotrophic factor and inflammatory markers in patients with early- vs. late-stage bipolar disorder.

Authors:  Marcia Kauer-Sant'Anna; Flávio Kapczinski; Ana C Andreazza; David J Bond; Raymond W Lam; L Trevor Young; Lakshmi N Yatham
Journal:  Int J Neuropsychopharmacol       Date:  2008-09-04       Impact factor: 5.176

10.  Individualized Prediction and Clinical Staging of Bipolar Disorders using Neuroanatomical Biomarkers.

Authors:  Benson Mwangi; Mon-Ju Wu; Bo Cao; Ives C Passos; Luca Lavagnino; Zafer Keser; Giovana B Zunta-Soares; Khader M Hasan; Flavio Kapczinski; Jair C Soares
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2016-03-01
View more
  5 in total

1.  Adverse Childhood Experiences Predict the Phenome of Affective Disorders and These Effects Are Mediated by Staging, Neuroimmunotoxic and Growth Factor Profiles.

Authors:  Michael Maes; Muanpetch Rachayon; Ketsupar Jirakran; Pimpayao Sodsai; Siriwan Klinchanhom; Monojit Debnath; Agnieska Basta-Kaim; Marta Kubera; Abbas F Almulla; Atapol Sughondhabirom
Journal:  Cells       Date:  2022-05-07       Impact factor: 7.666

2.  The Immune Profile of Major Dysmood Disorder: Proof of Concept and Mechanism Using the Precision Nomothetic Psychiatry Approach.

Authors:  Michael Maes; Muanpetch Rachayon; Ketsupar Jirakran; Pimpayao Sodsai; Siriwan Klinchanhom; Piotr Gałecki; Atapol Sughondhabirom; Agnieszka Basta-Kaim
Journal:  Cells       Date:  2022-03-31       Impact factor: 6.600

3.  The interleukin-6/interleukin-23/T helper 17-axis as a driver of neuro-immune toxicity in the major neurocognitive psychosis or deficit schizophrenia: A precision nomothetic psychiatry analysis.

Authors:  Hussein Kadhem Al-Hakeim; Ali Fattah Al-Musawi; Abbas Al-Mulla; Arafat Hussein Al-Dujaili; Monojit Debnath; Michael Maes
Journal:  PLoS One       Date:  2022-10-18       Impact factor: 3.752

4.  Inflammatory and Oxidative Pathways Are New Drug Targets in Multiple Episode Schizophrenia and Leaky Gut, Klebsiella pneumoniae, and C1q Immune Complexes Are Additional Drug Targets in First Episode Schizophrenia.

Authors:  Michael Maes; Aristo Vojdani; Sunee Sirivichayakul; Decio S Barbosa; Buranee Kanchanatawan
Journal:  Mol Neurobiol       Date:  2021-03-06       Impact factor: 5.590

5.  mRNA Expression of SMPD1 Encoding Acid Sphingomyelinase Decreases upon Antidepressant Treatment.

Authors:  Cosima Rhein; Iulia Zoicas; Lena M Marx; Stefanie Zeitler; Tobias Hepp; Claudia von Zimmermann; Christiane Mühle; Tanja Richter-Schmidinger; Bernd Lenz; Yesim Erim; Martin Reichel; Erich Gulbins; Johannes Kornhuber
Journal:  Int J Mol Sci       Date:  2021-05-27       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.